Should post-trial provision of beneficial experimental interventions be mandatory in developing countries?

Journal of Medical Ethics

Volumn 34, Issue 3, 2008, Pages 188-192

  Zong, Zhiyong ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL TRIAL; DEVELOPING COUNTRY; ETHICS; HEALTH CARE DELIVERY; HEALTH CARE PLANNING; MANDATORY PROGRAM; PATIENT CARE; PATIENT RIGHT; RESEARCH ETHICS;

CLINICAL TRIALS AS TOPIC; CONTINUITY OF PATIENT CARE; DEVELOPING COUNTRIES; ETHICS, RESEARCH; HEALTH PLANNING GUIDELINES; HEALTH SERVICES ACCESSIBILITY; MANDATORY PROGRAMS; PATIENT RIGHTS;

EID: 40649099658     PISSN: 03066800     EISSN: None     Source Type: Journal    
DOI: 10.1136/jme.2006.018754     Document Type: Article

References (29)

1. Participants in the 2001 Conference on ethical aspects of research in developing countries. Fair benefits for research in developing countries. Science 2002;298:2133-4.
2. The European group on ethics in science and new technologies to the European commission. Ethical Aspects of clinical research in developing countries 2003. http://europa.eu.int/comm/ european_group_grahics/docs/avisl7_en.pdf (accessed 5 Dec 2007).
3. Grady C. The challenge of assuring continued post-trial access to beneficial treatment. Yale J Health Policy Law Ethics 2005; 1:425-35.
4. The national commission for the protection of human subjects of biomedical and behavioral research. The Belmont report, ethical principles and guidelines for the protection of human subjects of research. 1979.
5. National Bioethics Advisory Commission. Ethical and policy issues in international research: clinical trials in developing countries, 2001. http://bioethics.georgetown.edu/nbac/pubs.html (accessed 5 Dec 2007).
6. Berkley S. Thorny issue in the ethics of AIDS vaccine trials. Lancet 2003;362:992.
7. Nuffield Council on Bioethics. The ethics of research related to healthcare in developing countries, 2002. http:// www.nuffieldbioethics.org/fileLibrary/pdf/errhdc_fullreport001.pdf (accessed 5 Dec 2007).
8. Indian Council of Medical Research. Ethical Guidelines for Biomedical Research on Human subjects. 2000, http:/[icmr.nic.in/ ethical.pdf (accessed 5 Dec 2007).
9. Clinical trial Working Group of the South Africa Department of Health. Guidelines for Good Practice in the Conduct of clinical trials in human participants in South Africa. http://www,doh.gov.za /docs/policy/trials/trials_presumble.html.
10. UNAIDS. Ethical considerations in HIV preventive vaccine research. 2000. http://data.unaids.org/Publications/IRC-pub01/ JC072-EthicalCons_en.pdf (accessed 2 Jun 2006).
11. World Medical Association. Declaration of Helsinki 2000. http://www.wma,net/e/policy/pdf/17c.pdf (accessed 5 Dec 2007).
12. National Consensus Conference on Bioethics in Uganda. Guidelines for the Conduct of Health research involving human subjects in Uganda. 1997.
13. National Health Council of Brazil. Resolution No. 196/96 on Research Involving Human Subjects. 1996.
14. Council for International Organisations of Medical Sciences. International ethical guidelines for biomedical research involving human subjects. 2002. http://www.cioms.ch/frame_guidelines_nov 2002.htm (accessed 5 Dec 2007).
15. National Bioethics Advisory Commission. Ethical and policy issues in international research: clinical trials in developing countries, 2001. http://bioethics.georgetown.edu/nbac/pubs.html (accessed 5 Dec 2007).
16. Medical Research Council of UK. Research involving human participants in developing societies. Ethical Guideline for MRC-sponsored studies. 2004. http://www.MRC.ac.uk/Utilities/ Documentrecord/index.htm?d = MRC002461 (access 12 Jan 08).
17. Nuffield Council on Bioethics. The ethics of research related to healthcare in developing countries: a follow-up Discussion Paper, 2005. http://www.nuffieldbioethics.org/fileLibrary/pdf/ HRRDC_Follow-up_Discussion_Paper001.pdf (accessed 5 Dec 2007).
18. Wilmshurst P. Scientific imperialism. Brit J Med 1997:314:840.
19. Ashcroft R. After the trial is over: what are the sponsor's obligations? Science and Development Network Website. 2005.http:// www.scidev.net/dossiers/index.cfm?fuseaction = policybrief&dossier = 5&policy = 63 (accessed 5 Dec 2007).
20. Cleaton-Jones PE. An ethical dilemma: availability of antiretroviral therapy after clinical trials with HIV infected patients are ended. Brit J Med 1997;314:887.
21. King P. A partnership to resolve the conundrum. Brit J Med 1997,314:890.
22. Wellcome Trust Guideline. Research Involving People living in developing countries. 2005. http://www.welicome.ac.uk/ doc_wtd015295.html (accessed 5 Dec 2007).
23. de Roy PG. Helsinki and the Declaration of Helsinki. World Med J 2004;50:9.
24. Ananworanich J, Cheunyam T, Teeratakulpisarn S, et al. Creation of a drug fund for post-clinical trial access to antiretrovirals. Lancet 2004;364:101-2.
25. Cohen J. Cambodian Leader Throws Novel Prevention Trial into Limbo. Science 2004;305:1092.
26. Greenwood B, Hausdorff WP. After a trial is over: the ethical issues. Science and Development Network Website. 2003. http:// www.scidev.net/dossiers/index.cfm?fuseaction = policybrief&dossier = 5&policy = 41 (accessed 5 Dec 2007).
27. Forster HP, Emanuel E, Grady C. The 2000 Revision of the Declaration of Helsinki: A Step Forward or More Confusion? Lancet 2001,358:1449-53.
28. World Medical Association. Workgroup Report on the revision of paragraph 30 of the declaration of Helsinki. 2003. http:/ /www.wma.net/e/pdf/wg_doh_sept2003.pdf (accessed 5 Dec 2007).
29. World Medical Association. Clarification on Declaration of Helsinki. 2004. http://www.wma.net/e/press/2004_24.htm (accessed 5 Dec 2007).